XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and...
COVID-19
Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in...
Cronos Group Reports 2023 Second Quarter Results
Industry-leading balance sheet with $841 million in cash and short-term investments Increased 2023 operating expense savings target to $20 to...
SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023
Robust growth and efficient expense execution continuesBOSTON and ROLLE, Switzerland, Aug. 08, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq:...
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease Commenced Recruitment for 540-patient Phase 2...
Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / August 8, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"),...
America’s Mental Health Crisis: Can Science Help End the Medication Guessing Game?
Fast-Tracking Relief: How RxGenomix's ExactMeds is Pioneering DNA-Guided Mental Health TreatmentFRANKLIN, TN / ACCESSWIRE / August 7, 2023 / Mental...
New Study Finds That Masimo SedLine® Patient State Index (PSi) Has the Potential to Improve Brain Monitoring for Patients Sedated with Dexmedetomidine
Masimo PSi, a Processed EEG Parameter, “Better Captured” Changes in Brain State Compared to Other Assessment MethodsIRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ:...
Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv
LAWRENCEVILLE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral...
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
JUPITER, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),...
Trinity Biotech Announces That It Has Received 510(k) Clearance From The U.S. Food and Drug Administration for the Premier Resolution System
DUBLIN, Ireland, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech has received U.S. Food and Drug Administration (FDA) 510(k) clearance...
Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France
-- Reimbursed early access program allows for patients with hypothalamic obesity in France to receive setmelanotide treatment ---- Early access...
Collegium Announces $50 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed...
Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on...
Helius Medical Technologies, Inc. Announces Participation of Montefiore Medical Center in its PoNS® Therapeutic Experience Program
Sixth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence...
Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID
Topline Results Expected Third Quarter 2023 Long COVID Afflicts Approximately 19% of Patients Following COVID-191, and is Expected to be...
Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights
– First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for the treatment of MTAP-deleted tumors...
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE...
XORTX Appoints Chief Financial Officer
CALGARY, Alberta, Aug. 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO and SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology...